A randomised controlled trial of a 12-dose rifapentine and isoniazid (RPT+INH) regimen using direct observed therapy (DOT) versus 6 months of daily isoniazid for latent tuberculosis infection (LTBI) in socially marginalised people
Latest Information Update: 10 Feb 2022
At a glance
- Drugs Rifapentine (Primary) ; Isoniazid
- Indications Tuberculosis
- Focus Therapeutic Use
- 10 Feb 2022 This trial has been discontinued in Denmark (End Date: 28 Jan 2022), according to European Clinical Trials Database record.
- 28 Apr 2017 New trial record